13/09/2017 18:05:41

RxS moves to new location to accommodate rapid growth

MANALAPAN, NJ, Sept. 13, 2017 (GLOBE NEWSWIRE) -- RxS LLC (“RxS”), a privately held company providing multi-channel sample management solutions to pharmaceutical and biotech companies, announced today its move to a new location to accommodate the company’s continued growth and success. Remaining in Manalapan, NJ, RxS is now operating at:

195 Route 9 S., Suite 208

Manalapan, NJ 07726

Pharmaceutical and biotech companies are often burdened by the regulations surrounding sample management, and that’s where RxS comes in. RxS offers customizable solutions for multi-channel sample management to companies of all sizes, ensuring compliance, state-of-the-art reporting, and outstanding customer service. “We are a service organization enabled by technology,” says Mark Jara, Principal, Managing Director. “Because RxS has proven to be a valuable business partner for so many companies, RxS has moved to a new location to accommodate our growth and success.”

RxS has maintained organizational growth year after year, including sales, clients, employees, and services.  Over the past two years they had a surge in new clients and business expansion. The new office space will support RxS’s promising trajectory as well as creating a high tech collaborative environment to optimize customer service and enhance technical development.

The move, however, is just one of several new developments for RxS. Concurrent to this action, the company is continuing the growth of its European footprint. In addition, RxS has entered the planning phase for a proposed satellite location in southeastern Florida slated to open by mid-2018.

RxS has become a leading provider of multi-channel sample management solutions. RxS’s growing presence and continued success is credited to its leadership team that collectively has more than 75 years of pharmaceutical expertise, along with the employees’ immense knowledge and understanding of the pharma and biotech industries. Beyond that, RxS has been built on technology and is committed to providing superior customer service.

By having technology at its core, RxS can provide offerings that ensure Prescription Drug Marketing Act compliance and also supply valuable reporting and analytics data. Customers can access up-to-date reporting and analytics data 24 hours a day, seven days a week, a feature that makes proactive monitoring possible. This results in customers having the tools to advance marketing reach and optimizing sample effectiveness.

Customer service is paramount to the team at RxS. In the client-supplier relationship, the company views itself as a business partner rather than simply a vendor as account representatives learn each client’s needs and provide client centric solutions designed to drive success. RxS has found this to be a most effective approach, as the solutions they provide clients are transparent and value-centric in terms of pricing.

RxS’s success is a direct reflection of the value it has provided and continues to provide its customers. For example, by applying industry experiences and a consultative approach, RxS was able to provide a small-sized client with guidance on best practices, lead-in project management and technical integrations during their first prescription representative product sampling launch. The result was an overwhelming success that relieved the client of startup complexities while achieving compliance through a solid forward thinking framework, on time and on budget.

The value RxS provides customers extends also to more established pharmaceutical and biotech companies. For instance, a client needed to transition from having multiple vendors to a consolidated solution, so RxS provided such a solution and also strategic value during the transition. RxS achieved this by working with numerous internal and external stakeholders to identify scope and requirements. The outcome was a solution that met the deadline and budget and also had a positive impact throughout the company, from headquarters to customers.

RxS works with companies of all sizes and provides truly client centric solutions that meet each client’s needs. To learn more about RxS offerings please visit rxsinfo.com. To schedule a visit to their new headquarters, please email sales@rxsinfo.com.

About RxS LLC

RxS LLC, a privately held company in Manalapan, New Jersey, is the leading provider of multi-channel sample management solutions for pharmaceutical and biotech companies. Supported by more than   75 years of combined pharmaceutical leadership experience, RxS has been partnering with pharmaceutical and biotech companies since its founding in 2011 to provide regulatory compliance in order to lessen the administrative burden of the Prescription Drug Marketing Act. RxS offerings go beyond regulatory compliance, providing solutions to increase marketing and sample effectiveness. Driven by technology, RxS offers a suite of proprietary services and software solutions to ensure regulatory compliance and maximize analytics data.

# # #

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3fa66210-a0be-4307-b66f-3fc3e92e4361

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/2c04c05e-388c-4cc6-a173-cef94eb39845

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/47e38a37-f9b1-41d3-883a-9ba03c746912

Drew Deeter

RxS

2153483890

drew@deeterusa.com

RxS moved to new office at 195 Route 9 S., Suite 208, Manalapan, NJ 07726

Interior photo of new RxS home office building.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
16 May
 
Hej,   Jeg har været herinde i dette forum siden 2010, og har fulgt mange debatører, men en af dem s..
28
17 May
PNDORA
Jeg personligt mener at en stor del af skribenterne her på forum og markedet som helhed overreagerer..
17
16 May
PNDORA
Pandora dykkede fordi der manglede 60 millioner i omsætning ud af 1.500 millioner. Det er jo helt gr..
16
09:51
PNDORA
Hej Enkommentar,   Du skrev i en besked i går til en anden debatør, om hvad det var i Pandora's regn..
15
19 May
PNDORA
Pandora realiserede i Q1 2018 en omsætning, som var 44 mDKK lavere end 1Q 2017, såfremt valutakurser..
15
17 May
NOVO-B
Trump fik fortalt at PBM'ernes rabatsystem er taget for fremskaffelse af lavere priser til patienter..
14
19 May
PNDORA
Når nu det kan være så svært, at tolke shortere, og andre på markedet, så kan det være en god ide, a..
13
18 May
DANSKE
Kongsmart, Jensen og Pedersen var de 3 sidste kandidater til en højt betroet post i banken. De mangl..
13
15 May
VELO
Har lyttet til det nu. Ikke så meget nyt, men bider mærke i, at Envarsus bliver mere og mere en fast..
13
14 May
VELO
Nu begynder Veloxis at levere varen. Det er klart, at med en vækst 142% i omsætning i forhold til Q1..
13

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
PRF: Consolidated Unaudited Interim Report of AS PRFoods for 1st quarter of 2018 and 15 months of 2017/2018
2
Cleveland Drug Rehabs, Addiction Isn’t A Disease, It’s Just A Thought in Your Head
3
ALGT LOSS ALERT: Rosen Law Firm Reminds Allegiant Travel Company Investors of Important Deadline in Class Action– ALGT
4
CRPA President Chuck Michel Offers the Following Statement on Santa Fe High School Incident
5
GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 May 2018 13:58:54
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180515.2 - EUROWEB4 - 2018-05-21 14:58:54 - 2018-05-21 13:58:54 - 1000 - Website: OKAY